PERBEDAAN GEJALA KLINIS DAN EFEK SAMPING PENGOBATAN PADA MALARIA FALCIPARUM DAN VIVAX

Santoso Santoso; Supargiyono Supargiyono; Mahardika Agus Wijayanti

doi:10.46774/pptk.v6i2.233

Santoso Santoso⁽¹⁾, Supargiyono Supargiyono⁽²⁾, Mahardika Agus Wijayanti⁽³⁾

(1) Loka Litbang P2B2 Baturaja
(2) Loka Litbang P2B2 Baturaja. Departemen Parasitologi, Fak.Kedokteran Univ.Gadjah Mada
(3) Loka Litbang P2B2 Baturaja. Departemen Parasitologi, Fak.Kedokteran Univ.Gadjah Mada
() Korespondensi Penulis

DOI: https://doi.org/10.46774/pptk.v6i2.233

Abstrak Dilihat: 3303 , PDF Unduh: 3127

Abstrak

Malaria is still a public health problem in Indonesia. Malaria-endemic areas continues to increase, accompanied by an increase in resistance to anti-malarial drugs. Ogan Komering Ulu (OKU) is a malaria endemic area in South Sumatra Province with Annual Malaria Insidence (AMI) in 2008 amounted to 21.79 per mile. The type of malaria which often develop into severe malaria is
falciparum malaria with symptoms that are common among the general fever, chills and sweating. In accordance with the policy of the Ministry of Health since 2004, the treatment of falciparum malaria using new drug combinations of artemisinin. As for the treatment of malaria vivaks started in 2008. Activities of malaria treatment using artemisinin combination drugs often cause side
effects that cause malaria treatment is often not appropriate dose. Based these conditions we conducted research that aims to determine differences in clinical symptoms and side effects of antimalaria drug in patients with falciparum malaria and malaria vivaks. The number of malaria patients were found as many as 35 people, ie 23 patients with falciparum malaria and 12 malaria patients vivax. Clinical symptoms of malaria are found in patients with chills, headache, dizziness, anorexia and muscle pain. Initial clinical symptoms before treatment were more common in patients with falciparum malaria (91%) than in patients with vivax malaria (50%). The results of statistical tests showed no significant difference between patients with falciparum malaria in malaria patients vivax to the emergence of early clinical symptoms. Artesdiakuin side effects found in the form of itching,
dizziness, nausea, vomiting and stomach pain.

Unduhan

Data unduhan belum tersedia.

Referensi

1. Harijanto P.N. Perubahan Radikal dalam Pengobatan Malaria di Indonesia. Cermin Dunia Kedokteran, 2006, 152: 30-36.
2. [Dinkes] Dinas Kesehatan Kabupaten OKU. Laporan Penemuan dan Pengobatan Penderita Malaria. Subdin P2P Dinkes Kabupaten OKU, 2009.
3. [Depkes] Departemen Kesehatan Republik Indonesia. Pedoman Penatalaksanaan Kasus Malaria di Indonesia. Dirjend. PP & PL., Jakarta, 2009.
4. Harijanto P.N., 2000. Gejala Klinik Malaria. Dalam: Malaria. Epidemiologi, Patogenesis, Manifestasi Klinis & Penanganan. Ed. P.N. Harijanto. Hal: 151-165. Penerbit Buku Kedokteran EGC.Jakarta.
5. WHO, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. World Health Organization. WHO Press, Geneva, Switzerland.
6. Becerra C.F., Sanz S., Brucet M.,Stanisic D.I., Alves F.P., Camargo E.P., Alonso P.L., Mueller I., Portillo H.A.D., 2010. Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay. Malaria Journal 9:29. http://www.malariajournal.com/content/9/1/29. Diakses pada tanggal 05 Mei 2010.
7. White N.J., Pongtavornpinyo W., Maude RJ., Saralamba S., Aguas R., Stepniewska K., Lee S.J., Dondorp A.M., White L.J. and Day N.P.J., 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malaria Journal 8:253. Diakses tanggal: 19 Juni 2010.
8. Lemeshow S., Hosmer Jr. D.W., Klar J., Lwanga S.K., 1997. Besar Sampel dalam Penelitian Kesehatan. Gadjah Mada University Press. Yogyakarta.
9. Susiawan L.D., 2006. Efikasi Artesdiaquine pada Pengobatan Malaria Falciparum tanpa Komplikasi di Kabupaten Banjarnegara. Tesis. Program Pasca Sarjana UGM.
10. Bousema J.T., Gouagna L.C., Drakeley C.J., Meutstege A.M., Okech B.A., Akim I.N.J., Beier J.C., Githure J.I. and Sauerwein R.W.
(2004). Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya. Malaria Journal 3:18. http://www.malariajournal.com/content/3/1/18. Diakses pada tanggal: 03 Desember 2009.
11. IDA Foundation, 2010. ACT: Artemisinin–based Combination Therapy. www.idafoundation.org. Diakses pada tanggal: 06 Juli 2010.
12. Adjei G.O., Kurtzhals, J.A.L., Rodrigues O.P., Alifrangis M., Hoegberg L.C.G., Kitcher E.D., Badoe E.V., Lamptey R. and Goka B.Q. (2008). Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malaria Journal, 7:127 doi:10.1186/1475-2875-7-127. http://creativecommons.org/licenses/by/2.0. Diakses pada tanggal: 06 Juli 2010.
13. Faye B., Offianan A.T., Ndiaye J.L., Tine R.C.., Toure W., Djoman K., Sylla K., Ndiaye P.S., Penali L., and Gaye O, 2010. Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus@) versus artemether-lumefantrine (Coartem@) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Tropical Medicine and International Health.Volume 15 no 5 pp 608–613.
Blackwell Publishing Ltd. Dakar,Senegal.
14. Priyanto, 2008. Farmakologi Dasar. Edisi II. Ed. Batubara L. Hal. 104-113. Leskonfi, Jabar.
15. WHO, 2010. Guidelines for the Treatment of Malaria. 2nd edition. World Health Organization. WHO Press, Geneva, Switzerland.